TCTC Holdings’s Halozyme HALO Stock Holding History

TCTC Holdings’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,813	Closed	-$107K	–	512
2023 Q3	$107K	Hold	2,813	–	–	﹤0.01%	220
2023 Q2	$101K	Hold	2,813	–	–	﹤0.01%	233
2023 Q1	$107K	Hold	2,813	–	–	﹤0.01%	231
2022 Q4	$160K	Buy	+2,813	New	+$144K	0.01%	190

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCTC Holdings's HALO Position: Q4 2023 in Review

TCTC Holdings sold out of Halozyme (HALO) in Q4 2023, closing a stake of 2,813 shares — an estimated $107K sold.

TCTC Holdings first reported a position in HALO in Q4 2022 and held it in 4 quarters. The position peaked at $160K in Q4 2022. 410 funds tracked by Wall St. Rank hold HALO as of Q4 2023.

TCTC Holdings reported no remaining Halozyme position as of Q4 2023 after selling out during the quarter.
TCTC Holdings sold 2,813 Halozyme shares in Q4 2023, an estimated $107K.
TCTC Holdings first reported a position in Halozyme in Q4 2022 and held it in 4 quarters.
TCTC Holdings's Halozyme position peaked at $160K in Q4 2022.
410 funds tracked by Wall St. Rank held Halozyme as of Q4 2023.

Based on TCTC Holdings's 13F filing for Q4 2023, filed 9 Feb 2024.